Patents Assigned to Institut National de la Sante et de la Recherche Medicale (Inserm)
  • Patent number: 10968253
    Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: April 6, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ECOLE NORMALE SUPERIEURE DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1
    Inventors: Théophile Ohlmann, Philippe Mangeot, Emiliano Ricci
  • Patent number: 10966940
    Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: April 6, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Auris Medical AG
    Inventors: Matthieu Guitton, Jean-Luc Puel, Remy Pujol, Jerome Ruel, Jing Wang
  • Patent number: 10961219
    Abstract: The present invention relates to a compound of formula (I) wherein P1, P3, P4 and P5 are amino acid residues. The invention also relates to a compound of formula (I) for its use as a Caspase-2 inhibitor and for its therapeutical use. It also concerns the use of a compound of formula (I) as activity base probe to selectively detect Caspase-2 activity.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: March 30, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PARIS DIDEROT-PARIS 7
    Inventor: Etienne Jacotot
  • Patent number: 10947260
    Abstract: A compound of following formula (I): where: X is O or S; A is an aromatic (hetero)cycle having 5 to 10 atoms selected from among carbon and nitrogen atoms, optionally being substituted; R? is H or (C1-C6)alkyl group; R1, R2, R3, R4 and R5, the same or different, are selected from the group formed by: H, (C1-C6)alkyl groups and (C6-C10)aryl groups. The compound is for the treatment of neurodegenerative diseases.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: March 16, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ECOLE PRATIQUE DES HAUTES ETUDES, ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER
    Inventors: Tangui Maurice, Jean-Noël Volle, David Virieux, Jean-Luc Pirat, Coralie Laborde
  • Patent number: 10925951
    Abstract: The present invention concerns a composition comprising at least one prophylactically or therapeutically active agent selected from the group consisting of attenuated Porphyromonas gingivalis, inactivated Porphyromonas gingivalis, a subunit of Porphyromonas gingivalis, a recombinant or isolated immunogenic polypeptide or peptide from Porphyromonas gingivalis or a c DNA from Porphyromonas gingivalis, for use as a vaccine for preventing or treating periodontitis, diabetes, obesity and/or complications thereof in a subject. The present invention also concerns an isolated antibody having specificity for Porphyromonas gingivalis for use for preventing or treating periodontitis, diabetes, obesity and/or complications thereof in a subject.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: February 23, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER
    Inventors: Vincent Blasco-Baque, Lucile Garidou, Rémy Burcelin
  • Patent number: 10888592
    Abstract: The present invention relates to pharmaceutical and food compositions for inducing satiation and prolonging satiety in subjects in need thereof. In particular, the present invention relates to a method of inducing satiation in a subject in need thereof comprising administering to the subject an effective amount of Hafnia alvei.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: January 12, 2021
    Assignees: TARGEDYS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Serguei Fetissov, Pierre Dechelotte, Jonathan Breton, Gregory Lambert, Romain Legrand, Nicolas Lucas
  • Patent number: 10881380
    Abstract: The present invention concerns a method for obtaining a functional parameter of a muscle having a part, the method comprising the steps of: a) applying ultrasound waves to the muscle, b) collecting the ultrasound waves retrodiffused by the muscle at a plurality of times, to obtain collected ultrasound waves, c) determining a first plurality of values representative of stiffness values of one part at a first plurality of times by using the collected ultrasound waves, d) determining a second plurality of values representative of deformation values of said part at a second plurality of times by using the collected ultrasound waves, and e) deducing at least one functional parameter based on the first plurality of values and the second plurality of values. The invention also concerns a corresponding device.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: January 5, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S), UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6), UNIVERSITE PARIS DIDEROT—PARIS 7, ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIMIE INDUSTRIELLES DE LA VILLE DE PARIS
    Inventors: Mickael Tanter, Mathieu Pernot
  • Publication number: 20200400685
    Abstract: The invention relates to biomarkers for typing or classifying allograft recipients as belonging to a transplant rejection group associated with antibody-mediated rejection (ABMR). The invention also provides for the treatment of typed allograft recipients suffering from antibody-mediated rejection by administration of an appropriate therapeutic agent.
    Type: Application
    Filed: December 27, 2018
    Publication date: December 24, 2020
    Applicants: VITO NV, Medizinische Hochschule Hannover, Katholieke Universiteit Leuven, Institut National de La Sante et de la Recherche Medicale (INSERM), APHP - Assistance Publique - Hôpitaux Paris, University Hospital Center of Limoges, Medizinische Hochschule Hannover
    Inventors: Inge Mertens, Hanny Willems, Maarten Naessens, Pierre Marquet, Dany Anglicheau, Marie Essig, Wilfried Gwinner
  • Patent number: 10864296
    Abstract: A polyelectrolyte coating comprises at least one polycationic layer consisting of at least one polyarginine as herein defined and at least one polyanionic layer consisting of hyaluronic acid. The polyelectrolyte coating has a biocidal activity and the invention thus further refers to the use of said polyelectrolyte coating for producing a device, in particular a bacteriostatic medical device, more particularly an implantable device, comprising said polyelectrolyte coating, and a method for preparing said device and a kit. Also disclosed is a method of preventing a bacterial infection in an individual.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: December 15, 2020
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ DE STRASBOURG, PROTIP MEDICAL
    Inventors: Philippe Lavalle, Pierre Schaaf, Nihal Engin Vrana, Angela Mutschler
  • Patent number: 10858306
    Abstract: The present invention concerns a method of synthesizing a iodo- or astatoarene comprising the reaction of a diaryliodonium compound with a iodide or astatide salt, respectively. The invention also relates to said iodo- or astatoarene and diaryliodonium compound as such. The invention also concerns a method of synthesizing a iodo- or astatolabelled biomolecule and/or vector using said iodo- or astatoarene.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: December 8, 2020
    Assignees: INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE NANTES, UNIVERSITE D'ANGERS, THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: François Guerard, Jean-François Gestin, Martin W. Brechbiel, Yong-Sok Lee
  • Publication number: 20200376104
    Abstract: Described herein are anti-CD277 antibodies which: activates or inhibit the cytolytic function of V?9/V?2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The use of said antibodies in therapy is also described.
    Type: Application
    Filed: June 9, 2020
    Publication date: December 3, 2020
    Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), UNIVERSITE D'AIX-MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE DE NANTES
    Inventors: Daniel OLIVE, Marc BONNEVILLE, Emmanuel SCOTET, Christelle HARLY, Yves GUILLAUME
  • Patent number: 10844109
    Abstract: The invention relates to a novel method for the synthesis of an erythrocyte protein, in which said protein is synthesized in an acellular system for the production of proteins, in the presence of at least one detergent which is non-ionic, of liposomes or of nanodiscs. The invention also relates to compositions comprising the proteins produced in this way.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: November 24, 2020
    Assignees: Institut National Transfusion Sanguine, Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris Diderot Paris 7
    Inventors: Isabelle Mouro-Chanteloup, Sandrine Genetet
  • Patent number: 10842635
    Abstract: A temporo-mandibular prosthesis including a glenoid part and a condylar part intended to be articulated relative to the glenoid part. The glenoid part including a glenoid support made in a metallic material; and a glenoid insert made in a non-metal lie material, and defining a seat for a head of said condylar part to define said articulation, wherein the glenoid support defines a housing having an opening through which said glenoid insert is insertable into said housing, said opening opening on an external side (E) of said glenoid support, the glenoid support comprising a tab configurable in a passive position and in an active position in which said tab allows and forbids, respectively, the insertion and the extraction, respectively, of said glenoid insert into and out of said housing, respectively.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: November 24, 2020
    Assignees: Institut National De La Sante Et De La Recherche Medicale (INSERM), Centre Hospitalier Regional Universitaire De Lille, Universite De Lille
    Inventor: Joel Ferri
  • Patent number: 10837981
    Abstract: A method of operating an atomic force microscope, comprising a probe, the probe being moved forth and back during respective trace and retrace times of a scan line, the method comprising: a) during trace time, oscillating the probe, b) generating a z feedback signal to keep an amplitude of oscillation of the probe constant at a setpoint value, the z feedback signal being generated by a first feedback loop, c) during retrace time, placing the probe in a drift compensation state by changing the setpoint value to a different value so that the z feedback signal being generated by the first feedback loop causes the probe to move away from the sample and oscillate free, d) detecting an amplitude of free oscillation of the probe and adjusting with a second feedback loop its excitation signal to maintain the amplitude of free oscillation of the probe close to a set value.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: November 17, 2020
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE D'AIX-MARSEILLE
    Inventors: Simon Scheuring, Atsushi Miyagi
  • Patent number: 10828342
    Abstract: The present invention relates to a method for preventing Gram-negative bacterial colonization of an oropharyngeal material, the said method comprising bringing into contact a composition comprising a cranberry-derived proanthocyanidin extract on at least a part of the surface area of the said material.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: November 10, 2020
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PARIS DIDEROT—PARIS 7, ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS
    Inventors: Jean-Damien Ricard, Dimitri Margetis
  • Patent number: 10832089
    Abstract: Provided herein is a method for determining the temporal progression of a biological phenomenon which may affect a studied subject, the method including the steps of providing first data relative to biomarkers for the studied subject, the biomarkers being relative to the progression of the biological phenomenon, providing a numerical model, converting the first data into at least one point on the same Riemann manifold, and using a numerical model to determine a temporal progression for the biological phenomenon for the studied subject, the numerical model being a function in a Riemann manifold, the numerical model associating to values of biomarkers a temporal progression trajectory for the biological phenomenon and data relative to the dispersion of the progression trajectory for the biological phenomenon among a plurality of subjects, the numerical model being obtained by using a stochastic approximation in an expectation-maximization technique on data relative to biomarkers.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: November 10, 2020
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE, ECOLE POLYTECHNIQUE, INRIA INSTITUT NATIONAL DE RECHERCHE EN INFORMATIQUE ET AN AUTOMATIQUE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, SORBONNE UNIVERSITÉ, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS
    Inventors: Stanley Durrleman, Jean-Baptiste Schiratti, Stéphanie Allassonniere, Olivier Colliot
  • Patent number: 10815272
    Abstract: The present invention provides peptides corresponding to fragments of CD31 that inhibit platelet and leukocyte activation, and to their use in the treatment of thrombotic disease. These peptides find use as therapeutic agents in the treatment of inflammatory diseases and thrombotic diseases such as atherothrombosis, in particular when immobilised onto solid supports.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: October 27, 2020
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PARIS DIDEROT—PARIS 7, UNIVERSITE PARIS 13—PARIS NORD, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS
    Inventors: Giuseppina Caligiuri, Antonino Nicoletti
  • Patent number: 10781452
    Abstract: The present invention relates to FLT3 receptor antagonists or inhibitors of FLT3 receptor gene expression for the treatment or the prevention of pain disorders.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: September 22, 2020
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE MONTPELLIER
    Inventor: Jean Valmier
  • Patent number: 10775387
    Abstract: The present invention relates to various soluble forms of CD31, including a novel form which is shed by activated platelets and released into the circulation. Methods for detecting said soluble forms of CD31 are disclosed, as are methods of specifically 1 detecting said platelet-derived shed CD31 and the use of such methods as a diagnostic tool.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: September 15, 2020
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE PARIS, UNIVERSITE PARIS 13—PARIS NORD, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS
    Inventors: Giuseppina Caligiuri, Antonino Nicoletti
  • Publication number: 20200283432
    Abstract: The present invention concerns a compound of formula (I): H or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity in particular ERK2 activity, it also concerns prodrugs of these compounds.
    Type: Application
    Filed: November 17, 2016
    Publication date: September 10, 2020
    Applicants: AGV Discovery ENSCM, Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Universite de Montpellier
    Inventors: Jean-François GUICHOU, Cédric BORIES, Clément GEOFFROY, Charline DUQUENNE, Muriel GELIN, Gilles LABESSE, Yannick BESSIN, Loic MATHIEU